

Application No. 10/670,472  
Amendment dated February 2, 2009  
Reply to Final Office Action of January 28, 2009

Docket No.: NY-LUD 5780.2

### AMENDMENTS TO THE CLAIMS

1. (Previously presented) An isolated peptide consisting of amino acid sequence ALKDVEERV (SEQ ID NO: 3).
- 2.-10. (Canceled)
11. (Previously presented) A method for determining if a cell presents an HLA-A2 molecule on its surface comprising contacting a sample containing said cell with the peptide of claim 1 and determining binding there between, said binding being indicative of HLA-A2 on the surface of said cell.
- 12-45. (Canceled)
46. (Canceled)
47. (Previously presented) A method for detecting presence of a cytolytic T cell (CTL) specific for a peptide consisting of the amino acid sequence of SEQ ID NO: 3 in a CTL containing sample, comprising contacting said sample with a tetramer comprising four biotinylated complexes of said peptide, a  $\beta_2$  microglobulin molecule and an HLA-A2 molecule, each of which is bound to an avidin molecule, and measuring release of tumor necrosis factor (TNF) released by a CTL, wherein an increase in level of TNF by said CTL containing sample, as compared to level of TNF release by said CTL containing sample in the absence of said tetramer, indicates presence of a CTL in said sample that is specific for said peptide.
48. (Previously presented) An isolated tetramer comprising four biotinylated complexes of a peptide consisting of the amino acid sequence of SEQ ID NO: 3, a

Application No. 10/670,472  
Amendment dated February 2, 2009  
Reply to Final Office Action of January 28, 2009

Docket No.: NY-LUD 5780.2

$\beta_2$  microglobulin molecule, and an HLA-A2 molecule, each of which is bound to an avidin molecule.

49. (Previously presented) The isolated complex of claim 48, further comprising a label.
50. (Previously presented) A composition comprising the isolated tetramer of claim 48, and a carrier.
51. (Canceled)